D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. - Wikidata - wikimedia - TriplyDB

D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.

D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.

http://www.wikidata.org/entity/Q37642428

about

Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders Virtual reality exposure-based therapy for the treatment of post-traumatic stress disorder: a review of its efficacy, the adequacy of the treatment protocol, and its acceptability Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders PTSD: from neurobiology to pharmacological treatments Emerging drugs for the treatment of anxiety D-cycloserine for treatment of numbing and avoidance in chronic post traumatic stress disorder: A randomized, double blind, clinical trial Fear-Potentiated Startle and Fear Extinction in a Sample of Undergraduate Women Exposed to a Campus Mass Shooting.GABA and NMDA receptors in CRF neurons have opposing effects in fear acquisition and anxiety in central amygdala vs. bed nucleus of the stria terminalis.An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trials Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats.The Use of Virtual Reality to Facilitate Mindfulness Skills Training in Dialectical Behavioral Therapy for Borderline Personality Disorder: A Case Study.Feasibility of articulated arm mounted Oculus Rift Virtual Reality goggles for adjunctive pain control during occupational therapy in pediatric burn patients Opposing effects of D-cycloserine on fear despite a common extinction duration: interactions between brain regions and behavior.Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder.On the resilience of remote traumatic memories against exposure therapy-mediated attenuation.D-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial.NMDA receptor activation regulates sociability by its effect on mTOR signaling activity.Psychopharmacological strategies in the management of posttraumatic stress disorder (PTSD): what have we learned?Investigational drugs under development for the treatment of PTSD.Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.Modulating fear extinction memory by manipulating SK potassium channels in the infralimbic cortex.An empirical review of potential mediators and mechanisms of prolonged exposure therapy.Virtual Reality-Enhanced Extinction of Phobias and Post-Traumatic Stress.The Use of Virtual Reality Technology in the Treatment of Anxiety and Other Psychiatric Disorders.Sleep Disturbance in Posttraumatic Stress Disorder: Epiphenomenon or Causal Factor?Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.A Meta-Analysis of D-Cycloserine in Exposure-Based Treatment: Moderators of Treatment Efficacy, Response, and Diagnostic Remission.On the Road to Translation for PTSD Treatment: Theoretical and Practical Considerations of the Use of Human Models of Conditioned Fear for Drug Development.Integrating NIMH Research Domain Criteria (RDoC) into PTSD Research.Genome-wide gene-based analysis suggests an association between Neuroligin 1 (NLGN1) and post-traumatic stress disorder.Pharmacological enhancement of mGluR5 facilitates contextual fear memory extinction.Concurrent Treatment with Prolonged Exposure for Co-Occurring Full or Subthreshold Posttraumatic Stress Disorder and Substance Use Disorders: A Randomized Clinical Trial.Optimizing the efficacy of exposure in PTSD treatment.Positive effects of the traditional Chinese medicine MLC901 in cognitive tasks.Review of Virtual Reality Treatment in Psychiatry: Evidence Versus Current Diffusion and Use.Clinical Virtual Reality tools to advance the prevention, assessment, and treatment of PTSD.Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: A randomized, placebo-controlled pilot trial.Selectively Bred Rats Provide a Unique Model of Vulnerability to PTSD-Like Behavior and Respond Differentially to FGF2 Augmentation Early in Life.

P2860

Q24187995-D36BB87A-1B25-4972-B9DE-A271FA85F61C Q26778474-AF5F7FE8-FC5E-4E61-BB5F-977EC57DE24B Q27006437-C1DA3E19-9BDD-49AC-9FF0-0843B24E911B Q28070159-1CA6153B-4CBC-422B-8AA9-002E9A44B62F Q28083141-DF1BD9C0-FB5B-4EFC-8BA3-F9BAB6C44EAD Q28396812-7CA1B3D9-FF63-4AEE-A38F-80A4F64DD975 Q30365336-B6CDB44A-7C2D-4243-8935-7AC2497922D9 Q30370972-DE53FEB9-E3CB-47E6-9337-9A5EBF095488 Q30375098-D877DBD6-CCC0-4AE7-9F91-D384E863F78E Q30433318-F4F17507-AAED-458D-A552-14878E8D54AD Q30585383-1A0CA83C-1AE2-42CD-AF31-F64CC8062D46 Q30695515-2C02379E-29FA-4273-B177-266BC116FAE9 Q30827060-D1159232-DD5E-4E61-B53C-3CC262B09E12 Q33705314-1A1DB195-F3C9-4A65-BE13-3F151008FA28 Q33740875-99AE1819-71D8-43BC-8104-5320C70F9104 Q34017493-7F2A9F9D-E397-410B-AAC2-6ED64F75BB4D Q34338841-63B41D7E-A205-41A0-AF53-EA4BD784B020 Q36712113-40E638F7-D4FF-46F5-961D-6AAF31E6ED93 Q38363808-A9E7603C-C605-4DC1-B6DF-D77346BA4AD9 Q38370133-7F871A2E-B9F0-4FF0-B0EF-B95A9F2C2385 Q38378939-2BA65770-4431-4E16-9648-A556EC3E8BE1 Q38390663-1CA15254-3434-4175-962C-811A4A3EB659 Q38561180-C862C84C-298B-4CB1-B00F-B8A91FE1190D Q38653367-55F0A624-883D-46D3-96D3-AC3CCA3B8D66 Q38682952-9C444573-E976-42E8-B90F-3DE25E4C9F41 Q38687385-53EF5962-7E76-465E-BFF8-1C9ECB2C2E42 Q38742568-8DC89341-C156-4A7F-AA44-62F6CD362B10 Q38787388-4754A3B2-AEFE-493E-9D97-5B95A3F6B97D Q38851779-5A6953E6-FE42-4F20-97D2-74E7812C79FA Q38852116-AB872B78-5B6C-4728-AD46-581BFC588EBC Q39200073-A60B59BE-E0B0-40F3-9546-14FEFC12ACDB Q39291412-414D9654-4479-465A-BAC5-0548923DD233 Q41846131-59B3DF42-93A7-4E43-8982-331F7A4F6CCD Q46521730-11DC1639-E0B1-48B8-ACD4-22DAEC85C4EB Q46705017-D3BF4A87-8E84-4B44-80CB-9890EA22AEF1 Q47425932-F27C402F-458B-4B75-A6F6-7D39CAE92A6C Q47568852-C2B68846-D0AE-4CB7-9802-B2A2DDAEADBE Q47645585-8D31D7D4-FEE6-4BAD-B382-147D75D97944 Q47665395-8F0FBDE2-3283-4E9F-B448-B8E165D4C3A9 Q47967975-EF1B3AF7-39CC-4DE6-B75C-47868C1247A3

P2860

D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.

http://www.wikidata.org/entity/Q37642428

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

D-cycloserine augmentation of ...... lot randomized clinical trial.

@en

D-cycloserine augmentation of ...... lot randomized clinical trial.

@nl

type

label

D-cycloserine augmentation of ...... lot randomized clinical trial.

@en

D-cycloserine augmentation of ...... lot randomized clinical trial.

@nl

prefLabel

D-cycloserine augmentation of ...... lot randomized clinical trial.

@en

D-cycloserine augmentation of ...... lot randomized clinical trial.

@nl

P1433

Q37642428-A3DA81CB-1FD0-4254-AB89-08517643B8E2

P1476

Q37642428-7F3200DC-53D3-4BC6-8DB5-42D264A0207C

P2093

Q37642428-2C7F65A9-C695-48D9-B937-3B189D07D632

Q37642428-505951E8-4DFD-450C-95C6-BED0FF88CA16

Q37642428-5512EBE1-8136-4400-8094-6AD7B0543A05

Q37642428-6313E99D-D72A-4C26-92E2-48BEAC69850F

Q37642428-6C0032CD-16D9-4421-AB76-CAD1B754202B

Q37642428-89CD33A7-9869-4319-AE18-D53C71DA28CC

Q37642428-E151132F-4BB2-4EF8-92CD-C9C37BDC9A16

P2860

Q37642428-0016A313-92EA-413E-A468-ED3B08A6EE3C

Q37642428-0A38EC7F-6908-449F-BB0B-5D5A43E76921

Q37642428-1303A0DC-28BB-40E2-A5CC-C2E02092A18D

Q37642428-22324B02-BCB9-452F-8F57-81198A71E79F

Q37642428-22740833-3707-433A-825C-97B37DDFD4B9

Q37642428-22E863CE-5982-4701-9CA3-9788A512745A

Q37642428-25FA2A52-3163-439E-BEBB-B126767EA2B5

Q37642428-26831001-3B3F-4C03-9D8D-58EF0D175B9C

Q37642428-286E3485-594D-4555-91B4-66FB99BC5A5C

Q37642428-35676A19-7D09-4715-A4E9-70ED3F2CC647

P2888

Q37642428-EEC7DF8B-2941-44DA-8F8F-DADBD03DDF23

P304

Q37642428-6C9F67A2-0A80-4E16-9B97-FCEBC296042B

P31

Q37642428-40A58B9E-0E9C-42FC-A0D9-BBFE2877354F

P356

Q37642428-C8AC3A09-6F14-4E44-AF7E-04B6848839E5

P407

Q37642428-4155558A-BCC4-4D9D-9E5C-9AE0D2AEBB2A

P433

Q37642428-5CFF7AF8-0C02-4795-8B5F-1EDFB1F221C4

P478

Q37642428-50A97456-3DEF-4BEB-8CE4-1EA00973EBD8

P577

Q37642428-EEB0D503-B4A1-449F-9F14-03D0E5B7149B

P5875

Q37642428-1381DB27-CD45-4E6C-B714-2AC104363CF9

P6179

Q37642428-F3AF6EAA-1C33-4937-8770-59A465AF826E

P698

Q37642428-CAF0E510-54F2-4A50-824E-BF2EAE89FAA2

P921

Q37642428-BC6147AA-DE30-44F7-BEDF-E2809081CD2E

P932

Q37642428-61E3B965-05D4-4E35-BC1D-3EA8915827D6

P356

P1433

Neuropsychopharmacology

P1476

D-cycloserine augmentation of ...... lot randomized clinical trial.

@en

P2093

Francis S Lee

http://www.w3.org/2001/XMLSchema#string

Hunter Hoffman

http://www.w3.org/2001/XMLSchema#string

JoAnn Difede

http://www.w3.org/2001/XMLSchema#string

Judith Cukor

http://www.w3.org/2001/XMLSchema#string

Katarzyna Wyka

http://www.w3.org/2001/XMLSchema#string

Margaret Altemus

http://www.w3.org/2001/XMLSchema#string

Megan Olden

http://www.w3.org/2001/XMLSchema#string

P2860

Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta-analysis

Stress-induced changes of hippocampal NMDA receptors: modulation by duloxetine treatment

Posttraumatic stress disorder in the National Comorbidity Survey

NMDA receptor antagonism in the basolateral but not central amygdala blocks the extinction of Pavlovian fear conditioning in rats.

Posttraumatic stress disorder: the burden to the individual and to society.

Posttraumatic stress disorder: epidemiology and health-related considerations.

Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care.

Posttraumatic stress disorder in the general population and in children.

Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.

Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

P2888

P304

1052-1058

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2013.317

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258444695

http://www.w3.org/2001/XMLSchema#string

P6179

1014788255

http://www.w3.org/2001/XMLSchema#string

P698

24217129

http://www.w3.org/2001/XMLSchema#string

P921

post-traumatic stress disorder

P932

3957110

http://www.w3.org/2001/XMLSchema#string